Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor.
about
Bypassing vasopressin receptor signaling pathways in nephrogenic diabetes insipidusPhysiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidneyA novel therapeutic effect of statins on nephrogenic diabetes insipidusNonsteroidal Anti-Inflammatory Drugs and the KidneyNephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.Familial forms of diabetes insipidus: clinical and molecular characteristics.Lithium-induced NDI: acetazolamide reduces polyuria but does not improve urine concentrating ability.Growth failure in an infant with congenital nephrogenic diabetes insipidus during sodium restrictionEGF Receptor Inhibition by Erlotinib Increases Aquaporin 2-Mediated Renal Water Reabsorption.Skewed X-chromosome inactivation causing diagnostic misinterpretation in congenital nephrogenic diabetes insipidus.V2 vasopressin receptor deficiency causes changes in expression and function of renal and hypothalamic components involved in electrolyte and water homeostasis.Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus.Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2.
P2860
Q24650150-A361699E-0A9F-4C9B-96A2-1A6A0CA63D32Q26771378-9093E747-036E-4B22-9898-C16C6287860FQ27005638-A0909FA7-4ADD-4944-B161-52E5FD2910D1Q28386844-EDE62A65-5CD8-4175-9840-BB5EEFEC64CFQ36724058-5AEA2BA1-53EA-4023-AB4B-789325961D64Q37897472-4561C104-6725-4FFF-A5EB-D7E9AE796A96Q38725462-FAEA2E72-5FBB-4B24-BAAB-B58499CE03DBQ39067421-62015FA4-849D-432C-B5FD-151B18508F24Q41645505-94412430-5F51-4E62-92BD-558539B7F8D5Q43066575-46B76CB7-4419-4A26-B77E-5EFC9DD516E0Q43781281-3A7F2B06-A024-4375-B803-7B4A72067BDCQ45220032-29DAFF85-71CD-4E06-9280-4A00A270DABDQ46794013-5AA688E7-9419-4E5B-86BD-34DD70157372
P2860
Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Treatment of congenital nephro ...... nd cyclooxygenase-2 inhibitor.
@en
Treatment of congenital nephro ...... nd cyclooxygenase-2 inhibitor.
@nl
type
label
Treatment of congenital nephro ...... nd cyclooxygenase-2 inhibitor.
@en
Treatment of congenital nephro ...... nd cyclooxygenase-2 inhibitor.
@nl
prefLabel
Treatment of congenital nephro ...... nd cyclooxygenase-2 inhibitor.
@en
Treatment of congenital nephro ...... nd cyclooxygenase-2 inhibitor.
@nl
P1433
P1476
Treatment of congenital nephro ...... nd cyclooxygenase-2 inhibitor.
@en
P2093
Anirut Pattaragarn
Uri S Alon
P2888
P304
P356
10.1007/S00467-003-1195-0
P577
2003-07-18T00:00:00Z